In future, patients should have access to innovative medicines on the day the product is authorised by Swissmedic («Day 0»).
In just a few years, Switzerland has fallen from first to fifth place in the Global Competitiveness Index (2019).
Our mission is to ensure that patients in Switzerland receive access to innovative medicines and therapies as quickly as possible.
People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.
show more articles
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2022
read more
Introducing Interpharma
read more
More about the tasks and overriding aims of Interpharma
read more
Contact us
read more
Latest information and media contacts for media representatives
read more
Download